Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-501 Monotherapy in Type 2 Diabetes
NCT01030679Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in fasting plasma glucose at 8 weeks. Started Jul 2007; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01030679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030679.